.jpg)
Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.
Cameron, Kim S., Quinn, Robert E.: 9780470650264: Books
Diagnosing and Changing Organizational Culture: Based on the Competing Values Framework
Clinical Trials in Glioblastoma ǀ Apogenix
a: The ambitious THORPEX organizational chart as proposed in the
Gene expression profiles in genome instability-based classes of colorectal cancer, BMC Cancer
Investors ǀ Apogenix
Apogee Property Management – a “high touch” property management service
Gene expression profiles in genome instability-based classes of colorectal cancer, BMC Cancer
Management Board ǀ Apogenix
Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition
GOVERNANCE
